

Freedom of Information Act 2000 - Request Reference FoI/23/433

Dermatology Drugs

Information Requested:

Q1. How many patients were treated in the last 4 months (April to July 2023) by the dermatology department with each of the following products:

- Abrocitinib: 1
- Acitretin: 122
- Alitretinoin: 11
- Azathioprine: 2
- Baricitinib: 7
- Ciclosporin: 10
- Dupilumab: 79
- Methotrexate: 12
- Mycophenolate mofetil: 0
- Pimecrolimus: 3
- Phototherapy (UVB or PUVA): 65 patients from April-August with PUVA and UVB
- Tacrolimus ointment: 10
- Tralokinumab: 2
- Upadacitinib: 5

Q2. How many patients were treated by the dermatology department in the previous 4-month period (December 22 - March 23) with Dupixent? 71

Q3. For patients treated by the dermatology department with Dupilumab in the four months from December 22 to March 2023, could you please tell us:

- a. How many patients were treated in the subsequent 4-month period (April - July 23) with Dupilumab? 67
- b. How many patients were treated in the subsequent 4-month period (April - July 23) with any of the following advanced therapies - Abrocitinib, Baricitinib, Tralokinumab and Upadacitinib? 4
- c. How many patients were treated in the subsequent 4-month period (April - July 23) with any of the following immunosuppressants - Methotrexate, Ciclosporin, Mycophenolate or Azathioprine? 0
- d. How many patients were treated in the subsequent 4-month period (April - July 23) with any of the following - Acitretin, Alitretinoin, Pimecrolimus or Tacrolimus? 1